BLTE•benzinga•
Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials
Summary
Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 18, 2025 by benzinga